Fuel

Pillar Fuels Second Go-Round With $100M Fund for Boston Startups

4 monthes ago   |   By Xconomy

It took a few more years than initially planned, but early-stage venture firm Pillar has raised the $100 million fund it wanted. Launching with fanfare in 2016 under former North Bridge Venture Partners' Jamie Goldstein, Pillar set its sights on nine digits worth of cash but ended up only raising $57 million. It has since sent that money into early stakes in 26 companies, including Algorand, Desktop Metal, PillPack, Circle, Flipside Crypto, Hometap, Kuebix, PathAI, and Asimov. Today, the firm announced passing that $100 million milestone with its second fund. Pillar partner Sarah Hodges...
Read more ...

 


Search by Tags

   Fuel      Boston      Boston blog main      Boston top stories      National blog main      Amazon      Carbonite      Circle      ClearSky Data      Constant Contact      Deals      Demandware      DraftKings      Ellen Rubin      Eric Paley      Founder Collective      Gail Goodman      Ginkgo BioWorks      Intelligent.ly      Iora Health      Jamie Goldstein      Jason Robins      Jeremy Allaire      Niraj Shah      North Bridge Venture Partners      Pillar      PillPack      Pluralsight      Reshma Shetty      Runkeeper      Rushika Fernandopulle      Sarah Hodges      Steve Conine      Steve Kaufer      Steve Kokinos      Tech      Tom Ebling      TripAdvisor      Venture Capital      WayFair      Yvonne Hao      Zilla Security  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

An Entrepreneur's Quest to Make Seattle a Genome Sciences Hub

An Entrepreneur's Quest to Make Seattle a Genome Sciences Hub

Ivan Liachko turned postdoctoral research at the University of Washington into a company whose genomics tools are now found in laboratories researching human, animal, and plant... Read more ...

Flagship's Omega Aims to Take Epigenetic Drugs a Step Further

Flagship's Omega Aims to Take Epigenetic Drugs a Step Further

A biotech startup called Omega Therapeutics debuts this morning touting a new approach to developing medicines based on epigenetics, a field of research that has tantalized... Read more ...

Topping the Medical Charts

San Diego Magazine “Physicians of Exceptional Excellence” survey, an annual opportunity for doctors across the region to vote for much-admired colleagues. ]]> ... Read more ...

Capturing extreme close-ups of cellular gene expression

Scientists studying genetic transcription are gaining new insights into a process that is fundamental to all life. Transcription is the first step in gene expression, the... Read more ...

Strip Steak: Bacterial Enzyme Removes Inflammation-Causing Meat Carbohydrates

Read more ...

Perturbed Genes Regulating White Blood Cells Linked to Autism Genetics and...

Read more ...

Ionis subsidiary Akcea ousts leadership team

Biotech veteran Damien McDevitt takes over as interim CEO... Read more ...

Enough with the Insanity. We Need to Fix Cybersecurity Now

The year 2019 has been another dreadful period for cyberattacks. The most notorious lowlights include: -More than 40 municipalities , including Baltimore, Albany and 22 cities... Read more ...

Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO

Mere weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul. Read more ...

Clovis strikes 3B deal to move into radiopharmaceuticals

Clovis Oncology has paid $12 million for rights to FAP-targeted radiopharmaceuticals in development at 3B Pharmaceuticals. The deal gives Clovis the ex-Europe rights to a... Read more ...